Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response

Journal of Viral Hepatitis

Volumn 19, Issue 5, 2012, Pages 332-340

  Clark, Paul J ^a,b   Thompson, A J ^a   Zhu, M ^c   Vock, D M ^a   Zhu, Q ^c   Ge, D ^c   Patel, K ^a   Harrison, S A ^d   Urban, T J ^c   Naggie, S ^a   Fellay, J ^c   Tillmann, H L ^a   Shianna, K ^c   Noviello, S ^e   Pedicone, L D ^e   Esteban, R ^f   Kwo, P ^g   Sulkowski, M S ^h   Afdhal, N ⁱ   Albrecht, J K ^e   Goldstein, D B ^c   McHutchison, J G ^a   Muir, A J ^a   more..

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c DUKE UNIVERSITY   (United States)

^d BROOKE ARMY MEDICAL CENTER   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g INDIANA UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ HARVARD UNIVERSITY   (United States)

Author keywords

Cholesterol; Hepatitis C virus; Interleukin 28B; Lipids; Sustained viral response

Indexed keywords

INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; CHOLESTEROL, LDL; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84859813739     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01553.x     Document Type: Article

References (33)

1. Agnello V, Ábel G, Elfahal M, Knight GB, Zhang Q-X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96(22): 12766-12771. (Pubitemid 29513577)
2. Boulant S, Montserret R, Hope RG et al. Structural determinants that target the hepatitis c virus core protein to lipid droplets. J Biol Chem 2006; 281(31): 22236-22247. (Pubitemid 44181927)
3. Miyanari Y, Atsuzawa K, Usuda N et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9(9): 1089-1097. (Pubitemid 47338147)
4. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008; 82(5): 2120-2129. (Pubitemid 351293514)
5. Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 2006; 44(3): 527-535. (Pubitemid 44433708)
6. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010; 21(1): 33-40.
7. Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38(1): 75-85. (Pubitemid 36775798)
8. Ramcharran D, Wahed AS, Conjeevaram HS et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010; 52(3): 854-863.
9. Harrison SA, Rossaro L, Hu KQ et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52(3): 864-874.
10. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34(3): 428-434. (Pubitemid 32240823)
11. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009; 50(4): 1030-1037.
12. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461(7262): 399-401.
13. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41(10): 1105-1109.
14. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41(10): 1100-1104.
15. Li JH, Lao XQ, Tillmann HL et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51(6): 1904-1911.
16. Cai T, Dufour J-F, Muellhaupt B et al. Viral genotype-specific role of PNPLA3, PPARG, MTTP and IL28B in hepatitis C virus-associated steatosis. J Hepatol 2011; 55 (3): 529-535.
17. Tillmann HL, Patel K, Muir AJ et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 2011; 55 (6): 1195-1200.
18. McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361(6): 580-593.
19. Fellay J, Thompson AJ, Ge D et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464(7287): 405-408.
20. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38(8): 904-909. (Pubitemid 44141658)
21. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81(3): 559-575. (Pubitemid 47330214)
22. Brown ML, Inazu A, Hesler CB et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989; 342(6248): 448-451. (Pubitemid 19277523)
23. Pennacchio LA, Olivier M, Hubacek JA et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001; 294(5540): 169-173. (Pubitemid 32952971)
24. Shinohara E, Yamashita S, Kihara S et al. Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 1997; 25(6): 1502-1506. (Pubitemid 27250776)
25. Moriishi K, Mochizuki R, Moriya K et al. Critical role of PA28c in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A 2007; 104(5): 1661-1666. (Pubitemid 46214647)
26. Wang AG, Lee DS, Moon HB et al. Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. J Pathol 2009; 219(2): 253-262.
27. Poordad F, Bronowicki J-P, Gordon SC et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genoytpe 1 treated with Boceprevir (BOC) combination therapy. J Hepatol 2011; 54(Suppl. 1): S6.
28. Pol S, Aerssens J, Zeuzem S et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial- or null responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. J Hepatol 2011; 54(Suppl. 1): S6.
29. Sarasin-Filipowicz M, Oakeley EJ, Duong FHT et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105(19): 7034-7039. (Pubitemid 351754525)
30. Chen L, Borozan I, Sun J et al. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 2010; 138(3): 1123-1133.
31. Honda M, Sakai A, Yamashita T et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139(2): 499-509.
32. Urban TJ, Thompson AJ, Bradrick SS et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52(6): 1888-1896.
33. Dill MT, Duong FHT, Vogt JE et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140(3): 1021-1031.